Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies

• Autores principales: Jiawang Liu (Autor), Nirmal Rajasekaran (Autor), Ahamed Hossain (Autor), Changde Zhang (Autor), Shanchun Guo (Autor), Borui Kang (Autor), Hunsoon Jung (Autor), Hongjoong Kim (Autor), Guangdi Wang (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2021-07-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to have high plasma protein binding in human and animal plasma,...